- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03739619
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the toxicity and determine the maximum tolerated dose (MTD) of combined gemcitabine, bendamustine, and nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma.
II. To determine the efficacy of bendamustine, gemcitabine, and nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma.
SECONDARY OBJECTIVES:
I. To evaluate the duration of response, progression-free survival, and overall survival for patients with relapsed/refractory classical Hodgkin lymphoma who receive gemcitabine, bendamustine, and nivolumab, including those who receive nivolumab maintenance.
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive gemcitabine intravenously (IV) over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, United States, 30342
- Emory Saint Joseph's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically documented classical Hodgkin lymphoma that is recurrent or refractory after standard chemotherapy. Core biopsies are acceptable if they contain adequate tissue for primary diagnosis and immunophenotyping. Bone marrow biopsies as the sole means of diagnosis are not acceptable. At least one biopsy-proven relapse is required for enrollment, but patients who have multiply relapsed disease do not require repeat biopsy if not clinically indicated
Prior treatment: patients must have relapsed or progressed after at least one prior therapy
- Patients with relapsed or refractory disease following autologous stem cell transplantation are permitted. Due to the risk of treatment-refractory graft versus host disease (GVHD), patients who have previously completed an allogeneic transplant are excluded.
- Patients may have received gemcitabine, bendamustine, or nivolumab in the past but may not have discontinued therapy due to toxicity felt to be related to that specific drug
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Measurable disease must be present either on physical examination or imaging studies. Non-measurable disease alone is not acceptable
Measurable disease
- Lesions that can be accurately measured in at least two dimensions as ≥ 1.0 x 1.0 cm by computerized tomography (CT), positron emission tomography (PET)/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI).
- If identified by PET/CT, there must be at least one lesion that demonstrates abnormal fludeoxyglucose (FDG) avidity, consistent with active disease. Ultrasound or physical examination alone may not be utilized to confirm measurable disease
Non-measurable disease
- All other lesions, including small lesions (less than 1.0 x 1.0 cm) and truly non-measurable lesions
Lesions that are considered non-measurable include the following:
- Bone lesions (lesions if present should be noted)
- Ascites
- Pleural/pericardial effusion
- Lymphangitis cutis/pulmonis
- Bone marrow (involvement by Hodgkin lymphoma should be noted)
- Non-pregnant and non-nursing. Women and men of reproductive potential should agree to use an effective means of birth control
- Patients with human immunodeficiency virus (HIV) infection are eligible. Patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; cluster of differentiation 4+ (CD4+) count ≥ 400/mm; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV ribonucleic acid (RNA)/mL. Patients with HIV must have ongoing follow-up with an infectious disease specialist and must have been evaluated within 90 days of cycle 1 day 1
- Patients with a history of hepatitis C are eligible as long as the hepatitis C has been treated and cleared and they have no evidence of hepatic dysfunction related to hepatitis C. Patients must have been seen by a hepatologist within 6 months of cycle 1 day 1
- Patients who test positive for hepatitis B core antibody may enroll on the study as long as they test negative for both hepatitis B surface antigen and hepatitis B deoxyribonucleic acid (DNA), and if they have no evidence of hepatic dysfunction that is felt to be related to hepatitis B
Patients must have adequate pulmonary function, defined as the following:
- No history of drug-related, radiation-induced, or autoimmune pneumonitis requiring hospital admission
- Baseline pulse oximetry reading of ≥ 92% on room air
- Patients with a history of asthma or chronic obstructive pulmonary disease (COPD) must have no oxygen requirement, must have not had a hospital admission for COPD/asthma exacerbation within the past 2 years, and must not have received systemic steroids (≥ 10 mg prednisone for more than 7 days) for asthma/COPD within the past 2 years
- Patients with hypothyroidism or type 1 diabetes mellitus that are on chronic hormonal therapy and which are well-controlled are eligible
- Granulocytes ≥ 1000/µl
- Platelet count ≥ 75,000/µl
- Creatinine clearance ≥ 50 mL/min
- Bilirubin ≤ 2.0 mg/dL
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.0 x upper limits of normal
Exclusion Criteria:
- Due to the teratogenic potential of these agents, pregnant or nursing patients may not be enrolled
- Patients may not have an auto-immune disease requiring systemic immunosuppression, biologic therapy, and/or steroid use (≥ 10 mg daily of prednisone or equivalent)
- Patients with current or prior central nervous system (CNS) involvement with lymphoma are not eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gemcitabine, bendamustine, nivolumab
Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1.
Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients may then receive nivolumab IV over 60 minutes on day 1.
Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerable dose (Phase I)
Time Frame: Up to completion of course 2 at 42 days after study start
|
Maximum tolerable dose will be defined as the highest dose level where at most 1 of 6 patients experience dose limiting toxicity (DLT).
|
Up to completion of course 2 at 42 days after study start
|
Complete response (CR) rate (Phase II)
Time Frame: Up to 2 years from discontinuation of study therapy
|
Complete response rate will be determined by dividing the number of CRs (per Lugano criteria) by the total number of evaluable patients.
|
Up to 2 years from discontinuation of study therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (Phase II)
Time Frame: Up to 2 years from discontinuation of study therapy
|
Overall response rate will be evaluated using Lugano criteria of response.
Overall response rate will be defined as the total number of patients achieving a partial response or CR as best response through cycle 6 divided by total number of patients treated.
|
Up to 2 years from discontinuation of study therapy
|
Duration of response (Phase II)
Time Frame: Up to 2 years from discontinuation of study therapy
|
Duration of response will be evaluated using Lugano criteria of response and will be determined from date of best response to progression or death.
|
Up to 2 years from discontinuation of study therapy
|
Progression free survival (PFS) (Phase II)
Time Frame: Up to 2 years from discontinuation of study therapy
|
Progression free survival will be evaluated using Lugano criteria and will be determined from date of first dose of study drug to progression or death.
|
Up to 2 years from discontinuation of study therapy
|
Overall survival (OS) (Phase II)
Time Frame: Up to 2 years from discontinuation of study therapy
|
Overall survival will be evaluated using Lugano criteria and will be determined from date of first dose of study drug to death from any cause.
|
Up to 2 years from discontinuation of study therapy
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathon Cohen, MD, MS, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Hodgkin Disease
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Bendamustine Hydrochloride
- Gemcitabine
Other Study ID Numbers
- IRB00104033
- P30CA138292 (U.S. NIH Grant/Contract)
- NCI-2018-02221 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- Winship4388-18 (Other Identifier: Emory University Hospital/Winship Cancer Institute)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin Lymphoma
-
National Cancer Institute (NCI)CompletedRecurrent Adult Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma | Adult Favorable Prognosis... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingClassic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin LymphomaUnited States
-
Northwestern UniversitySeagen Inc.; Robert H. Lurie Cancer CenterUnknownStage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin LymphomaUnited States, Canada, Puerto Rico
-
National Cancer Institute (NCI)The Lymphoma Academic Research OrganisationActive, not recruitingHIV Infection | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin... and other conditionsUnited States, France
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan